EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

A retrospective chart review to explore the efficacy and safety of switching to peficitinib in Japanese patients with rheumatoid arthritis and inadequate response to biologic disease-modifying antirheumatic drugs

Kunihiro Yamaoka iD, Junichi Kondo, Toshinori Furuya, Yusuke Tanaka, Tadatsura Koshika, Yoshiaki Morita, Kenji Oku

Modern Rheumatology · 2025

DOI: 10.1093/mr/roaf043 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Kunihiro Yamaoka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Kitasato University School of Medicine, Sagamihara-shi, Kanagawa, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Niacinamide, Adamantane. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Astellas Pharma, Astellas Pharma Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This retrospective, observational study examined the safety and efficacy of the Janus kinase inhibitor peficitinib in Japanese patients with rheumatoid arthritis who switched to peficitinib due to inadequate response to biologic disease-modifying antirheumatic drugs.

Methods

We included patients aged ≥ 20 years with rheumatoid arthritis who switched to peficitinib between 10 July 2019 and 31 March 2022 and were enrolled in peficitinib post-marketing surveillance. The primary endpoint was change in disease activity score in 28 joints with erythrocyte sedimentation rate (DAS28-ESR) from index date to 24 weeks. Secondary endpoints included change in Clinical Disease Activity Index and adverse event incidence.

Results

Of 76 enrolled patients, efficacy data were available for 67; 56 completed 24 weeks of treatment. One-quarter (19/76) of patients reported adverse events; 16 (21.1%) had drug-related adverse events with one (streptococcal infection) considered serious. From index date to 24 weeks, mean (standard deviation) change in DAS28-ESR was −0.95 (1.24) (95% confidence interval [CI]: −1.26, −0.65; P < .0001) and in Clinical Disease Activity Index was −7.82 (8.52) (95% CI: −9.90, −5.74; P < .0001). Improvements in DAS28-ESR and Clinical Disease Activity Index by 12 and 24 weeks were statistically significant regardless of prior number of biologic disease-modifying antirheumatic drugs.

Conclusions

Peficitinib could be an effective treatment option for patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsNiacinamideAdamantaneJanus Kinase InhibitorsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedJapanTreatment OutcomeDrug SubstitutionAdultSeverity of Illness IndexEast Asian People

Stichwörter der Autor:innen

CDAIDAS28bDMARDsinadequate responseobservationalpeficitinibreal-worldretrospectiverheumatoid arthritis

Substanzen

Antirheumatic AgentspeficitinibNiacinamideAdamantaneJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Rheumatology, Kitasato University School of Medicine, Sagamihara-shi, Kanagawa, Japan.
  • Kitasato University Medical Center, Saitama, Japan.
  • Astellas Pharma Inc., Tokyo, Japan.
  • Department of Rheumatology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.

ORCID-Profile: Kunihiro Yamaoka

Förderung

  • Astellas Pharma
  • Astellas Pharma Inc

Zitieren

APA

Yamaoka, K., Kondo, J., Furuya, T., Tanaka, Y., Koshika, T., Morita, Y., & Oku, K. (2025). A retrospective chart review to explore the efficacy and safety of switching to peficitinib in Japanese patients with rheumatoid arthritis and inadequate response to biologic disease-modifying antirheumatic drugs. Modern Rheumatology. https://doi.org/10.1093/mr/roaf043

Vancouver

Yamaoka K, Kondo J, Furuya T, Tanaka Y, Koshika T, Morita Y, et al. A retrospective chart review to explore the efficacy and safety of switching to peficitinib in Japanese patients with rheumatoid arthritis and inadequate response to biologic disease-modifying antirheumatic drugs. Modern Rheumatology. 2025. doi:10.1093/mr/roaf043

BibTeX
@article{Yamaoka2025,
  author = {Yamaoka, Kunihiro and Kondo, Junichi and Furuya, Toshinori and Tanaka, Yusuke and Koshika, Tadatsura and Morita, Yoshiaki and Oku, Kenji},
  title = {A retrospective chart review to explore the efficacy and safety of switching to peficitinib in Japanese patients with rheumatoid arthritis and inadequate response to biologic disease-modifying antirheumatic drugs},
  journal = {Modern Rheumatology},
  year = {2025},
  doi = {10.1093/mr/roaf043}
}
Kostenlos starten →